If you liked this article you might like

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance
Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal
Geron (GERN) Is Today's Strong On High Volume Stock
Geron (GERN) Is Weak On High Volume Today